Open Access

A Malignant Tumor Developed Seven Years After Small Cell Lung Cancer Treated With Etoposide-containing Chemotherapy

OKAUCHI SHINICHIRO 1
HATTORI SOU 1
OHARA GEN 1
TAKAYASHIKI NORIO 2
  &  
SATOH HIROAKI 1

1Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan

2Division of Pathology, Mito Medical Center, University of Tsukuba, Mito, Japan

Cancer Diagnosis & Prognosis Nov-Dec; 2(6): 716-719 DOI: 10.21873/cdp.10166
Received 14 August 2022 | Revised 13 July 2024 | Accepted 06 September 2022
Corresponding author
Hiroaki Satoh, MD, Ph.D., Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Miya-machi 3-2-7, Mito-city, Ibaraki, 310-0015, Japan. Tel: +81 292312371, Fax: +81 292215371 hirosato@md.tsukuba.ac.jp

Abstract

Background/Aim: Long-term survival of patients with small cell lung cancer (SCLC) is rare, and, to the best of our knowledge, there has been no SCLC patient who developed second malignancy after long-term survival. Case Report: A 66-year-old woman with a history of smoking was admitted to our hospital with a nodule in her right lung. She was diagnosed with cT2aN3M0 localized-SCLC. Chest irradiation and chemotherapy including etoposide was performed. A new nodule appeared in the right lung more than 7 years after the end of treatment for SCLC. A specimen obtained by bronchoscopic biopsy was pathologically confirmed to be a non-SCLC malignancy. Conclusion: There is a possibility of tumor development associated with etoposide, which is known to be carcinogenic, or residual tumor development from combined type SCLC. We could not confirm whether it was second malignancy or recurrence after long-term interval. The number of long-term survivors of SCLC is likely to increase in the future. The clinical course of this patient is interesting from the perspective of long-term survival of SCLC patients and might have implications for the treatment of patients with similar clinical course in the future.
Keywords: Etoposide, small cell lung cancer, second malignancy, recurrence, chemotherapy

Although it is difficult to obtain long-term control for small cell lung cancer (SCLC), expectations for cure are increasing due to the development of multidisciplinary therapies such as chemoradiotherapy and the addition of immune checkpoint inhibitors to the treatment (1,2). Among the chemotherapeutic drugs for SCLC, etoposide, a topoisomerase type I antitumor drug, is still considered to be a key antitumor drug (1,2). However, etoposide is evaluated to have a high incidence of secondary hematological malignancies (3,4). With SCLC treatment, the carcinogenicity of etoposide has not been an issue because there had been no long-term survivors, but it may become a problem if the prognosis improves in the future. In addition, transformation to SCLC after treatment for non-small cell lung cancer (NSCLC) has been reported (5-7). However, this transformation was observed in NSCLC patients treated with EGFR-TKI, ALK-TKI, or ICI (5-7).

We report herein a patient who developed non-SCLC malignancy after 7 years disease-free interval from the initiation of etoposide-containing chemotherapy. Regarding the development of the second malignancy other than SCLC in our patient, there was a possibility of secondary carcinogenesis due to etoposide, transformation from SCLC to other malignant tumor, or recurrence after a long period of time from residual components other than SCLC.

Case Report

A 66-year-old woman with a history of smoking 40 pack-years referred to our hospital due to abnormal opacities detected by chest radiograph taken at annual check-up in mass-screening. Physical examination was unremarkable. Chest radiography and CT scan revealed a mass in the right middle lobe with ipsilateral mediastinal lymph node swelling (Figure 1). A transbronchial biopsy of the lesion in the right middle lobe revealed small-sized tumor of cells possessing minimal cytoplasm and hyperchromatic indistinct nucleoli with abnormal mitosis. Immunohistochemical staining for CD56 and synaptophysin was positive (Figure 2). Imaging studies including brain magnetic resonance imaging (MRI), abdominal computed tomography (CT), and bone scan revealed no distant metastasis. Together with histopathological findings, the patient was diagnosed as having limited disease (LD)-SCLC. She was treated with 6 courses of chemotherapy with carboplatin and etoposide and 45 Gy irradiation to the primary lesion and mediastinum. The response to the chemotherapy was evaluated as complete response. Thereafter, the presence or absence of recurrence was monitored by periodic image evaluation, but there was no recurrence for more than 7 years. Chest CT performed 7 years and 7 months after the end of SCLC treatment revealed small nodules in both lungs and swelling of the lymph nodes in the ipsilateral mediastinum (Figure 3).

An endobronchial ultrasound-guided transbronchial needle aspiration from the nodule revealed that it was a malignant tumor other than SCLC. The results of immunostaining of the tumor were as follows: positive for vimentin and CD68, negative for thyroid transcription factor-1, pancytokeratin, CD56, synaptophysin, chromogranin A, S-100, desmin, and alpha-SMA. Proliferation of giant cells with histiocytic traits was confirmed (Figure 4). Chemotherapy with carboplatin and etoposide, and then with carboplatin and paclitaxel were administered, and good response was obtained. Therefore, she received supportive care. Two years after diagnosis, the patient died of the non-SCLC malignancy.

This study was approved by the institutional ethics committee of our institute (NO16-66). Written comprehensive informed consent at the time of admission for obtaining pathological specimens was obtained from the patient.

Discussion

In recent years, multidisciplinary therapies have increased the number of long-term survivors of SCLC (8-10). Factors such as low tumor volume, localized lesions in the thorax, and good response to first-line treatment are important for long-term survival of SCLC patients (11,12). Good nutrition and no systemic inflammation at the start of treatment are also considered prognostic factors (13). Immune checkpoint inhibitors (ICIs) can also be administered, and further improvement in prognosis is expected (14). As a chemotherapeutic agent to be used in combination with ICI, etoposide has been one of the key drugs for treatment of SCLC (1,2). Although etoposide still has been a key drug for SCLC, cases of secondary carcinogenesis have been reported (4). In addition, secondary malignancies after administration of etoposide for the treatment of pediatric malignancies have been reported (3,4). Recently, in contrast, changes from EGFR and ALK mutation-positive NSCLC to SCLC after TKI treatment have been reported (5,6). Similar transformation has also been reported in patients treated with immune checkpoint inhibitors (7). However, there has been no report of transformation of SCLC into other malignancies. The present patient with SCLC, who had been treated with etoposide-containing chemotherapy, developed malignant tumor derived from histiocytes after a 7-year disease free period.

It is well known that the majority of patients with SCLC smoke. Therefore, when a malignant tumor of the lung develops in SCLC patients at different times, it might be necessary to consider the effects of smoking more than etoposide treatment. There are few SCLC patients who have survived for a long time at this time, so it is not a clinical problem, but it might be a problem in the future. To our best knowledge, some reports of lung cancer developed after long-term SCLC control were found (8,10). Ishibashi et al. reported an SCLC patient with three malignant diseases 5 years after etoposide administration to SCLC (8). In this patient, there might be a possibility of development of second malignancy after etoposide therapy, or recurrence from non-SCLC components mixed in SCLC. Al-Ajam et al. presented a case of a patient with a10-year disease-free survival between two diagnoses of SCLC (10). This patient had LD-SCLC at the time of the initial diagnosis, but did not receive etoposide (10). In that patient, the possibility of SCLC recurrence and that of second SCLC might be considered. In our patient, it was not clear whether the non-SCLC malignancy should be considered as a second malignancy developed after etoposide treatment. It can be envisioned that SCLS changes to other malignancies after long-term management. It could not be ruled out that original malignancies mixed with SCLC regrew after a long management period. At present, ICIs are already available for ED-SCLC, and transformation of SCLC into other carcinomas might be reported in the future.

Conclusion

We reported this case as a clinical experience that gives suggestions for the treatment of cases that may have a similar course in the future. The accumulation of cases and the development of biological approaches are awaited.

Conflicts of Interest

The Authors have no conflicts of interest to declare in relation to this study.

Authors’ Contributions

SO and HS designed the study. SO, SH, GO, NT and HS collected the data. SO and HS analyzed the data and prepared the manuscript. All Authors approved the final version of the article.

References

1 Reddy HG Qin A & Kalemkerian GP Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors. Expert Opin Emerg Drugs. 25(3) 353 - 366 2020. PMID: 32683991. DOI: 10.1080/14728214.2020.1798929
2 Remon J Passiglia F Ahn MJ Barlesi F Forde PM Garon EB Gettinger S Goldberg SB Herbst RS Horn L Kubota K Lu S Mezquita L Paz-Ares L Popat S Schalper KA Skoulidis F Reck M Adjei AA & Scagliotti GV Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol. 15(6) 914 - 947 2020. PMID: 32179179. DOI: 10.1016/j.jtho.2020.03.006
3 Sneha LM Arockia J Suman FR & Khethan V Secondary acute myeloid leukemia in a child treated for retinoblastoma: A case report with review of literature. J Family Med Prim Care. 9(11) 5796 - 5798 2020. PMID: 33532438. DOI: 10.4103/jfmpc.jfmpc_1538_20
4 Pendleton M Lindsey RH Jr Felix CA Grimwade D & Osheroff N Topoisomerase II and leukemia. Ann N Y Acad Sci. 1310 98 - 110 2014. PMID: 24495080. DOI: 10.1111/nyas.12358
5 Zhang K & Yuan Q Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 12(Supplement) C131 - C137 2016. PMID: 28230005. DOI: 10.4103/0973-1482.200613
6 Kondoh C Horio Y Hayashi Y Ebi H Hida T Hasegawa Y & Yatabe Y Anaplastic lymphoma kinase expression in small-cell lung cancer. Histopathology. 75(1) 20 - 28 2019. PMID: 30790327. DOI: 10.1111/his.13842
7 Bar J Ofek E Barshack I Gottfried T Zadok O Kamer I Urban D Perelman M & Onn A Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer. Lung Cancer. 138 109 - 115 2019. PMID: 31683093. DOI: 10.1016/j.lungcan.2019.09.025
8 Ishibashi Y Tokuchi Y Kamachi M Harada M & Isobe H A case of a long-term survivor of small cell lung cancer developing triple second primary malignancies. Haigan. 42(2) 129 - 133 2002.
9 Tartarone A Lerose R Ardito R Troiani L Tedesco B Bozza G Cangiano R & Aieta M Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncol. 10(4) 523 - 528 2014. PMID: 24754583. DOI: 10.2217/fon.13.213
10 Al-Ajam M Seymour A Mooty M & Leaf A Ten years of disease-free survival between two diagnoses of small-cell lung cancer: a case report and a literature review. Med Oncol. 22(1) 89 - 97 2005. PMID: 15750201. DOI: 10.1385/MO:22:1:089
11 He Y Song L Wang H Chen P Liu Y Sun H Li X Dang S Liu G Liu X Chen S Zhang X Hofman P Uchino J Park HS Pacheco JM Tabbò F Xu M Dai J He K Yang Y Zhou C & written on behalf of the AME Lung Cancer Collaborative Group Mutational profile evaluates response and survival to first-line chemotherapy in lung cancer. Adv Sci (Weinh). 8(4) 2003263 2020. PMID: 33643802. DOI: 10.1002/advs.202003263
12 Kalemkerian GP Small cell lung cancer. Semin Respir Crit Care Med. 37(5) 783 - 796 2016. PMID: 27732999. DOI: 10.1055/s-0036-1592116
13 Kurishima K Watanabe H Ishikawa H Satoh H & Hizawa N Modified glasgow prognostic score in patients with small-cell lung cancer. Mol Clin Oncol. 7(1) 121 - 124 2017. PMID: 28685088. DOI: 10.3892/mco.2017.1261
14 Bianco A D’Agnano V Matera MG Della Gravara L Perrotta F & Rocco D Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment. Expert Rev Respir Med. 15(11) 1415 - 1425 2021. PMID: 34374626. DOI: 10.1080/17476348.2021.1964362